Pharmaceutical

ARIAD Pharmaceuticals’ new home in Cambridge, Mass., has 40,000 sf of high-tech biology and chemistry labs, along with four distinct space types to accommodate the work modes of its staff: focus, collaboration, learning, and social engagement. The new 130,000-rentable-square-foot headquarters, known by its address, 125 Binney Street, in the heart of the Kendall Square life science community, stands in marked contrast to the company’s existing facility, less than two miles away.

Pfizer will begin construction in mid-2017 on a $200 million research and development campus in Chesterfield, Mo. Supporting the creation of advanced vaccines, biotherapeutics, and pharmaceuticals, the project could include a 460,000-sf facility standing up to five stories high. The campus will be built by Clayco and its development subsidiary CRG, with Pfizer leasing the structures upon completion. Occupancy is expected in 2020.

The University of North Texas broke ground in October of 2016 on the Interdisciplinary Research and Education Building in Fort Worth. Supported by $80 million in state funding, the 173,000-sf facility will accommodate a progressive, team-based pedagogy for health sciences and interprofessional education. Designed by Treanor Architects, the building will house the College of Pharmacy, the North Texas Eye Research Institute, and the Institute for Molecular and Therapeutic Development.

ImmuCell broke ground in October of 2016 on a $20 million pharmaceutical manufacturing facility in Portland, Maine. The two-story, 16,800-sf facility will provide fermentation, processing, laboratory, and warehouse space for the production of Nisin, the active ingredient in one of ImmuCell's leading animal health products. Stantec is providing architectural and engineering services for the project, which is being built by Consigli Construction. Completion is expected in late 2017 with manufacturing operations commencing in early 2018.

Moderna Therapeutics began construction in October of 2016 on a $110 million clinical manufacturing facility in Norwood, Mass. Designed to meet current GMP and GLP standards, the 200,000-sf center will support the production of messenger RNA (mRNA) therapies and vaccines. DPS is providing architectural, engineering, construction management, commissioning, qualification, validation, and procurement services for the project. The clinical labs, offices, and ancillary spaces are being designed by TRIA.

Global pharmaceutical manufacturer Lonza is expanding its production facilities in Pearland, Texas. Work began in March of 2016 on a 100,000-sf clinical manufacturing center, which will begin operations in late 2017. A second phase of construction will begin in fall of 2016 at the site, providing an additional 150,000 sf of office, laboratory, and manufacturing space.

Merck KGaA is planning to construct a $56 million pharmaceutical packaging plant on the campus of its headquarters in Darmstadt, Germany. Designed as a packaging center of excellence, the flexible 161,460-sf facility will optimize energy savings through the use of advanced production technologies. Completion is expected in late 2017 with full operations commencing in mid-2018. The project will be constructed to meet the most stringent international Good Manufacturing Practices (GMP) standards.

GE Healthcare is planning to create a $167 million biopharmaceutical manufacturing campus in Ringaskiddy, Ireland. Featuring GE's prefabricated KUBio™ facilities, GE BioPark Cork will include four KUBio factories owned by independent biopharma companies. GE will manage the campus as well as providing centralized shared utilities and site services. Construction is expected to begin in mid-2017.

The University of Hawaii broke ground in September of 2016 on the $33.6 million Daniel K. Inouye College of Pharmacy in Hilo. Designed by SmithGroupJJR and WCIT Architecture, the two-story, 45,000-sf instructional facility will provide teaching labs, lecture halls, simulation training suites, and administrative offices. Isemoto Contracting has been awarded the $31.3 million contract for the construction of the pharmacy school and occupancy is expected in late 2018.

GSK (GlaxoSmithKline) is investing £275 million to expand its pharmaceutical manufacturing capacity at three sites in the United Kingdom. A £92 million aseptic sterile facility will be built at Barnard Castle, and a £110 million plant for the production of respiratory active ingredients will be constructed at Montrose in Scotland. Lastly, GSK will spend £74 million to create additional manufacturing capacity for the Ellipta respiratory inhaler at its Ware campus. GSK's global headquarters are located in Brentford in the United Kingdom.

Agilent Technologies will begin construction in fall of 2016 on a 130,000-sf pharmaceutical manufacturing facility in Frederick, Colo. Doubling the life science company's commercial production capacity for oligonucleotides, the project will support the creation of therapies based on nucleic acid active pharmaceutical ingredients (APIs). Agilent is based in Santa Clara, Calif.

The University of Nebraska Medical Center celebrated the opening of the $35 million Center for Drug Discovery and Lozier Center for Pharmacy Sciences and Education in August of 2016 in Omaha. Designed by The Clark Enersen Partners and RDG, the three-story, 85,000-sf teaching and research facility provides advanced drug discovery labs, a sterile compounding suite, classrooms, faculty offices, auditoriums, simulation training suites, and a model pharmacy. Ground was broken on the project in June of 2013.

DYNALABS completed a 15,500-sf expansion of its pharmaceutical testing facility in St. Louis in July of 2016. The $1.5 million project added wet and dry labs, offices, conference rooms, a glass wash, sample management and inspection areas, and storage and distribution space. Designed and constructed by The Artisan Building Co., the facility was delivered for less than half of the original cost estimates from other contractors, enabling DYNALABS to invest in further capital improvements such as the planned renovation of an existing cleanroom.

AstraZeneca is building the £750 million Global R&D Centre and Corporate Headquarters on the Cambridge Biomedical Campus in the United Kingdom. Providing advanced facilities for pharmaceutical discovery and development, the 580,000-sf project will include space for biologics research, high throughput screening, medicinal chemistry, pre-clinical research, and clinical studies. Designed to optimize interaction and connectivity, the collaborative 11-acre campus will accommodate approximately 2,000 employees and will include an on-site energy center.

Pfizer broke ground in late June of 2016 on the $350 million Global Biotechnology Center in China. Located in the Hangzhou Economic Development Area (HEDA), the facility will manufacture pharmaceutical biosimilars, which are drugs designed with similar active properties to existing licensed therapies. The project will feature a modular production facility created by GE Healthcare that utilizes flexible, single-use biomanufacturing technologies. The duration of construction will be 18 months with completion expected in early 2018.